$410m Ambit Deal Bolsters Daiichi Sankyo’s Oncology Presence
This article was originally published in PharmAsia News
Daiichi Sankyo's purchase of oncology-focused venture Ambit Biosciences for up to $410 million will bring the major Japanese firm an attractive Phase III asset for acute myeloid leukemia and boost its oncology pipeline.
You may also be interested in...
Join us for a brief audio tour around the past week's major global biopharma industry developments, in this podcast version of Scrip's Five Must-Know Things.
Highlighting progress it has made over the past few years, Japan’s regulatory agency says it wants to raise even further the number of “Japan-first” approvals, as part of its stated mission to get safe and effective new drugs to patients more quickly.
Join us for a brief audio tour around the past week's key developments in the global biopharma industry, in this podcast version of Scrip's Five Must-Know Things.